Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 32% year on year to $708.5 million. The company expects the full year’s revenue to be around $2.81 billion, close to analysts’ estimates. Its GAAP profit of $4.67 per share was 11.3% above analysts’ consensus estimates.
Is now the time to buy MEDP? Find out in our full research report (it’s free for active Edge members).
Medpace (MEDP) Q4 CY2025 Highlights:
- Revenue: $708.5 million vs analyst estimates of $686.1 million (32% year-on-year growth, 3.3% beat)
- EPS (GAAP): $4.67 vs analyst estimates of $4.19 (11.3% beat)
- Adjusted EBITDA: $160.2 million vs analyst estimates of $154.2 million (22.6% margin, 3.9% beat)
- EPS (GAAP) guidance for the upcoming financial year 2026 is $17.09 at the midpoint, beating analyst estimates by 3.7%
- EBITDA guidance for the upcoming financial year 2026 is $620 million at the midpoint, above analyst estimates of $604 million
- Operating Margin: 21.6%, down from 23.4% in the same quarter last year
- Organic Revenue rose 31.4% year on year (beat)
- Market Capitalization: $15.01 billion
StockStory’s Take
Medpace’s fourth quarter was marked by robust top-line growth and a significant year-over-year increase in revenue, but the market responded negatively, likely due to rising cancellations and margin pressure. CEO August Troendle acknowledged that “cancellations were elevated again in Q4,” with the highest backlog cancellations in over a year, particularly impacting the metabolic therapeutic area. This uptick in cancellations and a shift in business mix put downward pressure on operating margin, which declined compared to the prior year. Management described the business environment as “adequate and headed in the right direction,” but did not anticipate the spike in cancellations.
Management’s outlook for the coming year is shaped by expectations that cancellation levels will normalize and that the impact of metabolic trial mix will moderate over time. CFO Kevin Brady highlighted that pass-through costs are expected to start the year higher and then decline, reflecting a shift away from metabolics as a primary driver. Despite ongoing investment in AI, CEO August Troendle stated, “I would not anticipate really any productivity advantage…in 2026,” suggesting that near-term margin improvement will depend more on hiring discipline and productivity gains than on technology initiatives. Management remains focused on maintaining productivity through improved employee retention and measured hiring.
Key Insights from Management’s Remarks
Management attributed the quarter’s revenue surge to continued momentum in metabolic and oncology trials, but noted that an unexpected spike in cancellations weighed on backlog and margins.
- Metabolic trial mix impact: The increased share of metabolic studies, especially in diabetes and obesity, contributed to higher revenue but also drove a greater proportion of pass-through costs, reducing operating margins. CEO August Troendle noted that these trials are “very heavy on investigator fees,” which compresses profitability.
- Oncology remains strongest segment: Management emphasized that oncology continues to be the company’s most robust therapeutic area, with metabolic as the next largest. However, Troendle indicated that metabolic’s share of revenue is expected to decrease in the coming year, which may help stabilize margins.
- Elevated cancellations: The fourth quarter saw widespread cancellations across therapeutic areas, but particularly in metabolic. Troendle described the spike as broad-based rather than isolated to a few clients, and said, “I see no reason to expect the higher level of cancellations to continue but did not anticipate the spike in Q4.”
- Hiring and productivity strategy: President Jesse Geiger stated that headcount growth is expected to accelerate in 2026, with mid- to high-single-digit hiring planned to support demand. CFO Kevin Brady explained that improved employee retention has allowed for slower hiring and increased productivity, as less time is spent onboarding and training.
- AI investments underway: Management shared that AI is being integrated into process efficiency and data analytics, but Troendle cautioned that any productivity benefits are likely several years away. Initial AI initiatives will focus on operational enhancements and feasibility analytics, with an emphasis on maintaining data security and quality.
Drivers of Future Performance
Management expects revenue growth to moderate as the mix of metabolic trials declines and hiring remains disciplined, while margin improvement will rely on productivity rather than technology gains in the near term.
- Normalization of metabolic mix: CFO Kevin Brady expects the portion of revenue from metabolic trials—and associated pass-through costs—to decrease as 2026 progresses. This shift should provide some relief to margins, but management cautions that the change will be gradual rather than dramatic.
- Hiring and retention as margin levers: Management plans to keep headcount growth in the mid- to high-single digits, below projected revenue growth. Improved employee retention reduces the need for extensive training, supporting operational efficiency and modest margin improvement without major cost-cutting initiatives.
- Limited near-term AI impact: While Medpace is rolling out AI-enabled tools for process efficiency and data analytics, CEO August Troendle stated that “the investment is going to at least equal the benefits” in 2026, with any meaningful gains from technology expected in future years rather than immediately.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will focus on (1) whether cancellation levels return to historical norms and backlog conversion remains steady, (2) the pace at which metabolic trial mix shifts and its impact on margins, and (3) continued progress in AI and process efficiency initiatives. We will also monitor hiring trends and productivity gains as key contributors to margin stability.
Medpace currently trades at $456.44, down from $532 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
